Llama antibodies can soon be playing a role in the global fight against COVID-19 if clinical trials live up to their early promise. The trials are being conducted by a Belgian biomedical start-up.

Researchers from the Flemish Institute for Biotechnology and Ghent University Center for Medical Biotechnology are saying that antibodies from a llama named Winter have blunted the coronavirus infections in lab testing. The technology wouldn¢¥t be used to replace vaccines but rather to add to them, helping to protect people with weaker immune systems and those hospitalized by the virus.

Llamas have a particular kind of antibody called heavy chain antibody, and they¢¥re much simpler than the ones that humans have. Due to this, scientists can easily take a little snippet of the protein and glue it to other proteins. Early studies showed effectiveness against several variants of the disease, including the highly infectious delta variant.

Difficult words: biomedical (relating to both biology and medicine), blunt (to weaken), snippet (a small part or piece).